<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486770</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-11-01</org_study_id>
    <nct_id>NCT02486770</nct_id>
  </id_info>
  <brief_title>Study of Single Doses of IV Aerucin in Healthy Adults</brief_title>
  <official_title>A Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aridis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aridis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety profile and pharmacokinetic behavior of a single&#xD;
      administration of Aerucin in healthy adults at three different dosages.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase I trial will be conducted as an open label trial in 15 healthy adults. All&#xD;
      subjects will receive a specific intravenous dose of Aerucin. There are three study groups,&#xD;
      each with a specific dose of Aerucin. Study Group 1 will receive 2.0 mg/ kg of Aerucin .&#xD;
      Study Group 2 will receive 8.0 mg/kg of Aerucin . Study Group 3 will receive 20 mg/kg of&#xD;
      Aerucin . The dose levels of Aerucin are selected for this study based on animal studies&#xD;
      showing protection in an animal model and absence of adverse effects in toxicological&#xD;
      studies. Groups will be enrolled sequentially.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 and 84 days following dosing</time_frame>
    <description>Number and % of subjects experiencing adverse events following dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>24 and 84 days following dosing</time_frame>
    <description>Number and % of subjects experiencing Serious Adverse Events following dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited Adverse Events</measure>
    <time_frame>7 days following dosing</time_frame>
    <description>Number and % of subjects experiencing Solicited Adverse Events following dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMax -Observed maximum plasma concentration</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Pharmacokinetics Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMax-Time to reach maximum plasma concentration</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Pharmacokinetics Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last Area under the the concentration time curve</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Pharmacokinetics Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ Area under the concentration time curve from zero to infinite time</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Pharmacokinetics Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal phase elimination rate</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Pharmacokinetics Characteristics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Pharmacokinetics Characteristics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-Aerucin Antibodies</measure>
    <time_frame>84 days following dosing</time_frame>
    <description>Exploratory analysis-evaluation of development of antibodies may be performed</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerucin 2.0mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerucin 8.0mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aerucin 20.0mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerucin 2.0mg/kg</intervention_name>
    <description>IV Aerucin 2.0 mg/kg over 1 hour</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerucin 8.0mg/kg</intervention_name>
    <description>IV Aerucin 8.0 mg/kg over 1 hour</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aerucin 20.0 mg/kg</intervention_name>
    <description>IV Aerucin 20 mg/kg over 1 hour</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has completed the written informed consent process&#xD;
&#xD;
          2. Is male or female&#xD;
&#xD;
          3. Is age ≥18 years and ≤50 years&#xD;
&#xD;
          4. Agrees to stay in contact with the study site for the duration of the study, provide&#xD;
             updated contact information as necessary, and has no current plans to move from the&#xD;
             study area for the duration of the study&#xD;
&#xD;
          5. Agrees to avoid elective surgery for the duration of the study&#xD;
&#xD;
          6. For female subjects: agrees to have avoided pregnancy from 14 days prior to Study Day&#xD;
             0 through the duration of the study. Women physically capable of pregnancy (not&#xD;
             sterilized and still menstruating or within 1 year of the last menses if menopausal)&#xD;
             in sexual relationships with men must use an acceptable method of avoiding pregnancy&#xD;
             during this period. Acceptable methods of avoiding pregnancy include: a sterile sexual&#xD;
             partner; sexual abstinence (not engaging in any sexual intercourse); hormonal&#xD;
             contraceptives (oral, injection, transdermal patch, or implant); vaginal ring;&#xD;
             intrauterine device (IUD); or condom.&#xD;
&#xD;
          7. Has general good health, confirmed by medical history and physical examination&#xD;
&#xD;
          8. Has body mass index (BMI) between 18 and 30 (weight/height) -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Oral temperature ≥37.5°C&#xD;
&#xD;
          2. Abnormal CBC laboratory values (per local laboratory parameters) from blood collected&#xD;
             at screening (&gt;5% above ULN or &gt;5% below LLN)&#xD;
&#xD;
          3. Abnormally elevated laboratory values (per local laboratory parameters) from blood&#xD;
             collected at screening for ALT, AST, total bilirubin, alkaline phosphatase (ALP),&#xD;
             blood urea nitrogen (BUN), creatinine (Cr), (&gt;10% above ULN)&#xD;
&#xD;
          4. Abnormal urinalysis that, in the opinion of the investigator, is clinically&#xD;
             significant&#xD;
&#xD;
          5. Positive screening urine test for illicit drugs (opiates, cocaine, amphetamines)&#xD;
&#xD;
          6. Has received an immunoglobulin product in the 120 days prior to Study Day 0&#xD;
&#xD;
          7. History or evidence of autoimmune disease&#xD;
&#xD;
          8. History or evidence of any past, present, or future possible immunodeficiency state,&#xD;
             including laboratory evidence of HIV 1 infection.&#xD;
&#xD;
          9. History or evidence of chronic hepatitis&#xD;
&#xD;
         10. History of evidence of Pseudomonas infection&#xD;
&#xD;
         11. Received a systemic antibiotic with 14 days prior to Study Day 0&#xD;
&#xD;
         12. Participation in any other investigational study during the study period&#xD;
&#xD;
         13. Received immunoglobulin or blood products within 90 days prior to Study Day 0&#xD;
&#xD;
         14. Received any investigational drug therapy or investigational drug within 60 days prior&#xD;
             to Study Day 0&#xD;
&#xD;
         15. Received immunosuppressive medications other than inhaled or topical&#xD;
             immunosuppressants within 45 days prior to Study Day 0&#xD;
&#xD;
         16. Inability to discontinue daily medications during the study other than: oral&#xD;
             contraceptives, vitamins, nonprescription nutritional supplements, aspirin,&#xD;
             antihistamines inhaled corticosteroids, inhaled beta agonists, inhaled&#xD;
             anticholinergics&#xD;
&#xD;
         17. All female subjects: currently pregnant or lactating/nursing; positive screening urine&#xD;
             pregnancy test; or positive urine pregnancy test on the day of any study dosing&#xD;
&#xD;
         18. History or evidence of allergic disease or reaction that, in the opinion of the&#xD;
             investigator, may compromise the safety of the subject&#xD;
&#xD;
         19. History or evidence of any other acute or chronic disease that, in the opinion of the&#xD;
             investigator, may interfere with the evaluation of the safety or immunogenicity of the&#xD;
             drug or compromise the safety of the subject&#xD;
&#xD;
         20. Medical, psychiatric, occupational, or substance abuse problems that, in the opinion&#xD;
             of the investigator, will make it unlikely that the subject will comply with the&#xD;
             protocol&#xD;
&#xD;
         21. Any other reason at discretion of the investigator -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Al-Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SNBL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL-CPC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

